Quick Answer
NEKTAR THERAPEUTICS reported Cash and Equivalents of $15.12 million for fiscal year 2025.
NEKTAR THERAPEUTICS Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.12M | -65.8% |
| 2024 | $44.25M | +25.4% |
| 2023 | $35.28M | -60.0% |
| 2022 | $88.23M | +249.9% |
| 2021 | $25.22M | -87.3% |
| 2020 | $198.96M | +106.5% |
| 2019 | $96.36M | -50.6% |
| 2018 | $194.91M | +3992.9% |
| 2017 | $4.76M | -92.0% |
| 2016 | $59.64M | +7.3% |
| 2015 | $55.57M | +349.4% |
| 2014 | $12.37M | -68.3% |
| 2013 | $39.07M | +53.6% |
| 2012 | $25.44M | +66.1% |
| 2011 | $15.31M | -13.8% |
| 2010 | $17.75M | -64.2% |
| 2009 | $49.60M | -68.1% |
| 2008 | $155.58M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $41.03M | +36.3% | -4.6% |
| June 30, 2025 | $42.99M | +53.9% | +10.5% |
| March 31, 2025 | $38.89M | -20.0% | -12.1% |
| December 31, 2024 | $44.25M | +25.4% | +47.0% |
| September 30, 2024 | $30.11M | -53.6% | +7.8% |
| June 30, 2024 | $27.94M | -44.9% | -42.6% |
| March 31, 2024 | $48.64M | -36.8% | +37.9% |
| December 31, 2023 | $35.28M | -60.0% | -45.7% |
- NEKTAR THERAPEUTICS showed a decrease of -65.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, NEKTAR THERAPEUTICS’s cash and equivalents has declined by 90.3% (from $155.58 million to $15.12 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: